8 research outputs found
Quantitative, Multi-institutional Evaluation of MR Thermometry Accuracy for Deep-Pelvic MR-Hyperthermia Systems Operating in Multi-vendor MR-systems Using a New Anthropomorphic Phantom
Clinical outcome of hyperthermia depends on the achieved target temperature, therefore
target conformal heating is essential. Currently, invasive temperature probe measurements are the
gold standard for temperature monitoring, however, they only provide limited sparse data. In contrast,
magnetic resonance thermometry (MRT) provides unique capabilities to non-invasively measure
the 3D-temperature. This study investigates MRT accuracy for MR-hyperthermia hybrid systems
located at five European institutions while heating a centric or eccentric target in anthropomorphic
phantoms with pelvic and spine structures. Scatter plots, root mean square error (RMSE) and
Bland–Altman analysis were used to quantify accuracy of MRT compared to high resistance thermistor
probe measurements. For all institutions, a linear relation between MRT and thermistor probes
measurements was found with R
2
(mean ± standard deviation) of 0.97 ± 0.03 and 0.97 ± 0.02,
respectively for centric and eccentric heating targets. The RMSE was found to be 0.52 ± 0.31 ◦C and
0.30 ± 0.20 ◦C, respectively. The Bland-Altman evaluation showed a mean difference of 0.46 ± 0.20 ◦C
and 0.13 ± 0.08 ◦C, respectively. This first multi-institutional evaluation of MR-hyperthermia hybrid
systems indicates comparable device performance and good agreement between MRT and thermistor
probes measurements. This forms the basis to standardize treatments in multi-institution studies of
MR-guided hyperthermia and to elucidate thermal dose-effect relations
A multi-institution study: comparison of the heating patterns of five different MR-guided deep hyperthermia systems using an anthropomorphic phantom
Introduction
Within the hyperthermia community, consensus exists that clinical outcome of the treatment radiotherapy and/or chemotherapy plus hyperthermia (i.e. elevating tumor temperature to 40 − 44 °C) is related to the applied thermal dose; hence, treatment quality is crucial for the success of prospective multi-institution clinical trials. Currently, applicator quality assurance (QA) measurements are implemented independently at each institution using basic cylindrical phantoms. A multi-institution comparison of heating quality using magnetic resonance thermometry (MRT) and anatomical representative anthropomorphic phantoms provides a unique opportunity to obtain novel QA insights to f
Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centers.
PURPOSE
To analyze the current practice of regional hyperthermia (RHT) for soft tissue sarcoma (STS) at 12 European centers to provide an overview, find consensuses and identify controversies necessary for future guidelines and clinical trials.
METHODS
In this cross-sectional survey study, a 27-item questionnaire assessing clinical subjects and procedural details on RHT for STS was distributed to 12 European cancer centers for RHT.
RESULTS
We have identified seven controversies and five consensus points. Of 12 centers, 6 offer both, RHT with chemotherapy (CTX) or with radiotherapy (RT). Two centers only offer RHT with CTX and four centers only offer RHT with RT. All 12 centers apply RHT for localized, high-risk STS of the extremities, trunk wall and retroperitoneum. However, eight centers also use RHT in metastatic STS, five in palliative STS, eight for superficial STS and six for low-grade STS. Pretherapeutic imaging for RHT treatment planning is used by 10 centers, 9 centers set 40-43 °C as the intratumoral target temperature, and all centers use skin detectors or probes in body orifices for thermometry.
DISCUSSION
There is disagreement regarding the integration of RHT in contemporary interdisciplinary care of STS patients. Many clinical controversies exist that require a standardized consensus guideline and innovative study ideas. At the same time, our data has shown that existing guidelines and decades of experience with the technique of RHT have mostly standardized procedural aspects.
CONCLUSIONS
The provided results may serve as a basis for future guidelines and inform future clinical trials for RHT in STS patients
Quality assurance for clinical studies in regional deep hyperthermia
A guideline is provided for the implementation of regional deep hyperthermia treatments under strict rules of quality assurance. The objective is to guarantee a comparable and comprehensible method in the treatment and scientific analysis of hyperthermia. The guideline describes regional deep hyperthermia (RHT) and MR-controlled partial body hyperthermia (PBH) of children, young and adult patients. According to this guideline, hyperthermia treatment is always applied in combination with chemotherapy and/or radiotherapy. The guideline is based on practical experience from several hyperthermia centers. The procedure allows applying jointly coordinated standards and quality control in hyperthermia for studies. The guideline contains recommendations for hyperthermia treatments, including indication, preparation, treatment, and standardized analysi
Desmoplastic small round cell tumors : Multimodality treatment and new risk factors
Background: To evaluate optimal therapy and potential risk factors. Methods: Data of DSRCT patients <40 years treated in prospective CWS trials 1997‐2015 were analyzed. Results: Median age of 60 patients was 14.5 years. Male:female ratio was 4:1. Tumors were abdominal/retroperitoneal in 56/60 (93%). 6/60 (10%) presented with a localized mass, 16/60 (27%) regionally disseminated nodes, and 38/60 (63%) with extraperitoneal metastases. At diagnosis, 23/60 (38%) patients had effusions, 4/60 (7%) a thrombosis, and 37/54 (69%) elevated CRP. 40/60 (67%) patients underwent tumor resection, 21/60 (35%) macroscopically complete. 37/60 (62%) received chemotherapy according to CEVAIE (ifosfamide, vincristine, actinomycin D, carboplatin, epirubicin, etoposide), 15/60 (25%) VAIA (ifosfamide, vincristine, adriamycin, actinomycin D) and, 5/60 (8%) P6 (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide). Nine received high‐dose chemotherapy, 6 received regional hyperthermia, and 20 received radiotherapy. Among 25 patients achieving complete remission, 18 (72%) received metronomic therapies. Three‐year event‐free (EFS) and overall survival (OS) were 11% (±8 confidence interval [CI] 95%) and 30% (±12 CI 95%), respectively, for all patients and 26.7% (±18.0 CI 95%) and 56.9% (±20.4 CI 95%) for 25 patients achieving remission. Extra‐abdominal site, localized disease, no effusion or ascites only, absence of thrombosis, normal CRP, complete tumor resection, and chemotherapy with VAIA correlated with EFS in univariate analysis. In multivariate analysis, significant factors were no thrombosis and chemotherapy with VAIA. In patients achieving complete remission, metronomic therapy with cyclophosphamide/vinblastine correlated with prolonged time to relapse. Conclusion: Pleural effusions, venous thrombosis, and CRP elevation were identified as potential risk factors. The VAIA scheme showed best outcome. Maintenance therapy should be investigated further